Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alicaforsen - Atlantic Healthcare

Drug Profile

Alicaforsen - Atlantic Healthcare

Alternative Names: Alicaforsen sodium; AP 1007; AP 1431; AP 1450; AP 1451; Camligo; ISIS 2302

Latest Information Update: 26 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Atlantic Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis

Highest Development Phases

  • Preregistration Pouchitis
  • Phase III Ulcerative colitis
  • Preclinical Crohn's disease
  • Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 29 Oct 2018 Atlantic Pharmaceuticals completes a phase III trial in Pouchitis in Belgium, Canada, England, France, Ireland, Israel, Italy, Netherlands, Switzerland, United Kingdom, USA (NCT02525523)
  • 27 Sep 2018 Atlantic Healthcare plans to initiate a phase IIb efficacy trial in Crohn’s disease (PO, Tablet)
  • 02 May 2018 Atlantic Healthcare completes enrolment in its phase III trial for Pouchitis in USA, Belgium, Canada, France, Ireland, Israel, Italy, Netherlands, Switzerland and United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top